全文获取类型
收费全文 | 213篇 |
免费 | 10篇 |
国内免费 | 2篇 |
学科分类
医药卫生 | 225篇 |
出版年
2023年 | 1篇 |
2022年 | 8篇 |
2021年 | 16篇 |
2020年 | 4篇 |
2019年 | 9篇 |
2018年 | 11篇 |
2017年 | 5篇 |
2016年 | 4篇 |
2015年 | 5篇 |
2014年 | 21篇 |
2013年 | 15篇 |
2012年 | 6篇 |
2011年 | 13篇 |
2010年 | 6篇 |
2009年 | 6篇 |
2008年 | 6篇 |
2007年 | 11篇 |
2006年 | 3篇 |
2005年 | 6篇 |
2004年 | 7篇 |
2003年 | 3篇 |
2002年 | 4篇 |
2001年 | 1篇 |
2000年 | 1篇 |
1999年 | 6篇 |
1998年 | 1篇 |
1997年 | 5篇 |
1996年 | 1篇 |
1995年 | 2篇 |
1994年 | 5篇 |
1993年 | 3篇 |
1992年 | 2篇 |
1991年 | 5篇 |
1989年 | 2篇 |
1988年 | 3篇 |
1986年 | 1篇 |
1985年 | 4篇 |
1984年 | 1篇 |
1982年 | 3篇 |
1981年 | 2篇 |
1980年 | 2篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1967年 | 1篇 |
排序方式: 共有225条查询结果,搜索用时 0 毫秒
1.
通过纤维细胞集落(CFU-F)的培养,观察了急性早幼粒细胞性白血病(APL)的CFU-F,结果APL 患者较正常骨髓明显低下(4.3±1.63/2×10~5细胞)(n=9);完全缓解后则上升达正常水平(12.4±2.55/2×10~5)。体外试验,维甲酸(RA)加入CFU-F 培养系后,CFU-F 下降为3.11±1.24/2×10~5细胞,明显低于对照组8.5±1.57/2×10~5(P<0.05)。提示RA 对骨髓纤维细胞有抑制作用,此结果可能为RA 治疗骨髓纤维化提供初步依据。 相似文献
2.
P. Harten H. H. Euler E. Wolf G. Delling H. Löffler 《Journal of molecular medicine (Berlin, Germany)》1994,72(11):878-882
Histoplasma infections in Europe are rare, and acute disseminated histoplasmosis has only been observed in immunocompromised persons. We describe a case of acute disseminated histoplasmosis in a young, nonimmunocompromised European woman. The probable source of infection was Sri Lanka or the Maldives. At presentation she was severely ill with fever, lymphadenopathy, anemia, thrombocytopenia, hepatosplenomegaly, and polyserositis. Histologically, myelofibrosis and osteosclerosis were observed with extramedullary hematopoiesis. Histoplasma capsulatum yeasts were detected in bone marrow trephine biopsy by methenamine silver staining. Treatment with conventional and liposomal amphotericin B and subsequent itraconazole led to rapid and complete recovery.Abbreviations He
Histoplasma capsulatum
- AIDS
acquired immunodeficiency syndrome
- HIV
human immunodeficiency virus 相似文献
3.
沙利度胺治疗原发性骨髓纤维化临床疗效观察 总被引:1,自引:0,他引:1
目的探讨沙利度胺治疗原发性骨髓纤维化(IMF)的临床有效性。方法IMF患者10例,剂量150mg/d,同时羟基脲1.0~3.0mg/d仍维持治疗。根据治疗前后血液学指标白细胞计数、血红蛋白测定、血小板计数和肝脾大小测定的变化及腹胀和下肢浮肿的改善来评定疗效。结果10例脾大患者,9例明显缩小,其中7例巨脾患者5例缩小更显著;2例肝大患者2例恢复正常;5例白细胞升高患者,1例明显降低,2例恢复正常;6例轻中度贫血患者,1例有所上升,2例贫血纠正;4例血小板升高患者,1例明显降低,3例恢复正常。9例腹胀患者,4例好转,3例消失;7例双下肢浮肿患者,2例好转,4例消失。10例IMF患者中,仅2例出现轻度不良反应。结论沙利度胺治疗原发性骨髓纤维化有一定疗效。 相似文献
4.
5.
Bruno Deltreggia Benites Carolina Silva Costa Lima Irene Lorand-Metze Marcia Torresan Delamain Gislaine Borba Oliveira Daiane de Almeida Carmino Antonio de Souza Jose Vassallo Katia Borgia Barbosa Pagnano 《Clinics (S?o Paulo, Brazil)》2013,68(3):339-343
OBJECTIVES:
To evaluate whether risk scores used to classify patients with primary myelofibrosis and JAK-2 V617F mutation status can predict clinical outcome.METHODS:
A review of clinical and laboratory data from 74 patients with primary myelofibrosis diagnosed between 1992 and 2011. The IPSS and Lille scores were calculated for risk stratification and correlated with overall survival.RESULTS:
A V617F JAK2 mutation was detected in 32 cases (47%), with no significant correlation with overall survival. The patients were classified according to the scores: Lille - low, 53 (73.%); intermediate, 13 (18%); and high, 5 (7%); and IPSS – low, 15 (26%); intermediate-1, 23 (32%); intermediate-2, 19 (26%); and high, 15 (31%). Those patients presenting a higher risk according to the IPSS (high and intermediate-2) had a significantly shorter overall survival relative to the low risk groups (intermediate-1 and low) (p = 0.02).CONCLUSIONS:
These results emphasize the importance of the IPSS prognostic score for risk assessment in predicting the clinical outcome of primary myelofibrosis patients. 相似文献6.
Antoine N. Saliba Alejandro Ferrer Naseema Gangat Rajiv K. Pruthi Ayalew Tefferi Alexandra Higgins Evandro D. Bezerra Alessia Buglioni Mohamed E. Salama Eric W. Klee Filippo Pinto e Vairo Abhishek Mangaonkar Julie Majerus Dong Chen Mrinal M. Patnaik 《British journal of haematology》2020,190(5):e316-e320
7.
《Clinical Lymphoma, Myeloma & Leukemia》2014,14(1):31-36
IntroductionPhiladelphia chromosome-negative myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), and are characterized by clonal proliferation of hematopoietic cells in the bone marrow. There are numerous case reports and reviews reporting patients with coexisting MPN and plasma-cell disease such as multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS).MethodsWe report 15 patients treated at our institution over a 5-year period (January 2008 to December 2012) with a diagnosis of both an MPN and MGUS or MM. We also reviewed and summarized published case reports and studies describing the coexistence of these two disease entities.ResultsMost patients (12/15) had an MPN diagnosis made before or at the same time as the MGUS/MM diagnosis. Eventually, 2 patients developed a lymphoid leukemia, 1 patient developed lymphoma, and 1 patient developed acute myeloid leukemia, raising the question of whether patients with coexistence of myeloid- and lymphoid-derived neoplasms are more prone to leukemic or lymphomatous transformation. We did not find any treatment-related effect that could have contributed to the development of coexisting MGUS or MM and MPN. Of the 7 patients with an abnormal karyotype, 3 patients had trisomy 8.ConclusionAt present, management strategies are aimed at treating the MPN and regularly monitoring the MGUS for transformation to an overt plasma-cell malignancy. However, for patients who develop overt MM, management is focused more on treating the myeloma and monitoring the MPN. It has not yet been definitively shown that these 2 entities arise from a common-ancestor hematopoietic stem cell. 相似文献
8.
9.
Kavita Raj Diderik-Jan Eikema Donal P McLornan Eduardo Olavarria Henric-Jan Blok Stefania Bregante Fabio Ciceri Jakob Passweg Per Ljungman Nicolaas Schaap Kristina Carlson Tsila Zuckerman Liesbeth C. de Wreede Liisa Volin Yener Koc Jose Luis Diez-Martin Peter Brossart Dominik Wolf Nicolaus Kroger 《Biology of blood and marrow transplantation》2019,25(3):522-528
This analysis included 56 myelofibrosis (MF) patients transplanted from family mismatched donor between 2009 and 2015 enrolled in the European Society for Blood and Marrow Transplantation database. The median age was 57years (range, 38 to 72); 75% had primary MF and 25% had secondary MF. JAK2 V617F was mutated in 61%. Donors were HLA mismatched at 2 or more loci. Stem cells were sourced from bone marrow in 66% and peripheral blood in 34%. The median CD34+ cell dose was 4.8?×?106/kg (range, 1.7 to 22.9; n?=?43). Conditioning was predominantly myeloablative in 70% and reduced intensity in the remainder. Regimens were heterogeneous with thiotepa, busulfan, fludarabine, and post-transplant cyclophosphamide used in 59%. The incidence of neutrophil engraftment by 28days was 82% (range, 70% to 93%), at a median of 21days (range, 19 to 23). At 2years the cumulative incidence of primary graft failure was 9% (95% CI 1% to 16%) and secondary graft failure was 13% (95% CI 4% to 22%). The cumulative incidence of acute graft-versus-host disease (GVHD) grades II to IV and III to IV was 28% (95% CI 16% to 40%) and 9% (95% CI 2% to 17%) at 100days. The cumulative incidence of chronic GVHD at 1 year was 45% (95% CI 32% to 58%), but the cumulative incidence of death without chronic GVHD by 1 year was 20% (95% CI 10% to 31%). With a median follow-up of 32 months, the 1- and 2-year overall survival was 61% (95% CI 48% to 74%) and 56% (95% CI 41% to 70%), respectively. The 1- and 2- year progression-free survival was 58% (95% CI 45% to 71%) and 43% (95% CI 28% to 58%), respectively, with a 2-year cumulative incidence of relapse of 19% (95% CI 7% to 31%). The 2-year nonrelapse mortality was 38% (95% CI 24% to 51%). This retrospective study of MF allo-SCT using family mismatched donors demonstrated feasibility of the approach, timely neutrophil engraftment in over 80% of cases, and acceptable overall and progression-free survival rates with relapse rates not dissimilar to the unrelated donor setting. However, strategies to minimize the risk of graft failure and the relatively high nonrelapse mortality need to be used, ideally in a multicenter prospective fashion. 相似文献
10.